The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eo, S. K.
Right arrow Articles by Rouse, B. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eo, S. K.
Right arrow Articles by Rouse, B. T.
The Journal of Immunology, 2001, 166: 5473-5479.
Copyright © 2001 by The American Association of Immunologists

Prime-Boost Immunization with DNA Vaccine: Mucosal Route of Administration Changes the Rules1

Seong Kug Eo*, Malgorzata Gierynska*, Amal Abou Kamar{dagger} and Barry T. Rouse2,*

* Department of Microbiology, University of Tennessee, Knoxville, TN 37996; and {dagger} Department of Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

In this study we assessed prime-boost immunization strategies with a DNA vaccine (gB DNA) and attenuated recombinant vaccinia virus vector (rvacgB), both encoding the gB protein of HSV, for their effectiveness at inducing mucosal as well as systemic immunity to HSV. Confirming the reports of others, systemic priming with gB DNA and systemic boosting with rvacgB were the most effective means of inducing serum Ab and splenic T cell responses. Nevertheless, the systemic prime-boost approach failed to induce detectable humoral or T cell responses at mucosal sites. However, such responses, at both proximal and distal locations, were induced if immunizations, especially the priming dose, were administered mucosally. Curiously, whereas optimal immunity with systemic priming and boosting occurred when gB DNA was used to prime and rvacgB was used as a boost, mucosal responses were optimal when animals were mucosally primed with rvacgB and boosted with gB DNA given mucosally. Furthermore, notable mucosal responses also occurred in animals mucosally primed with rvacgB and subsequently boosted systemically with gB DNA. Because the mucosal prime-boost immunization protocol also induced excellent systemic immune responses, the approach should be useful to vaccinate against agents for which both mucosal and systemic immunity are important for protection.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al.
Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity
J Natl Cancer Inst, July 2, 2008; 100(13): 950 - 961.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
M. M. Gherardi and M. Esteban
Recombinant poxviruses as mucosal vaccine vectors
J. Gen. Virol., November 1, 2005; 86(11): 2925 - 2936.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. N. Toka, S. Suvas, and B. T. Rouse
CD4+ CD25+ T Cells Regulate Vaccine-Generated Primary and Memory CD8+ T-Cell Responses against Herpes Simplex Virus Type 1
J. Virol., December 1, 2004; 78(23): 13082 - 13089.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. W. Peacock, S. K. Nordone, S. S. Jackson, H.-X. Liao, N. L. Letvin, A. G. Yafal, L. Gritz, G. P. Mazzara, B. F. Haynes, and H. F. Staats
Gender Differences in Human Immunodeficiency Virus Type 1-Specific CD8 Responses in the Reproductive Tract and Colon following Nasal Peptide Priming and Modified Vaccinia Virus Ankara Boosting
J. Virol., December 1, 2004; 78(23): 13163 - 13172.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Devito, B. Zuber, U. Schroder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, and J. Hinkula
Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity
J. Immunol., December 1, 2004; 173(11): 7078 - 7089.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. O. Lasaro, W. B. Luiz, M. E. Sbrogio-Almeida, L. S. Nishimura, B. E. C. Guth, and L. C. S. Ferreira
Combined Vaccine Regimen Based on Parenteral Priming with a DNA Vaccine and Administration of an Oral Booster Consisting of a Recombinant Salmonella enterica Serovar Typhimurium Vaccine Strain for Immunization against Infection with Human-Derived Enterotoxigenic Escherichia coli Strains
Infect. Immun., November 1, 2004; 72(11): 6480 - 6491.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. M. Gherardi, E. Perez-Jimenez, J. L. Najera, and M. Esteban
Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule
J. Immunol., May 15, 2004; 172(10): 6209 - 6220.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
B. Garulli, Y. Kawaoka, and M. R. Castrucci
Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus
J. Virol., January 15, 2004; 78(2): 1020 - 1025.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. N. Toka, M. Gierynska, and B. T. Rouse
Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1
J. Virol., December 1, 2003; 77(23): 12742 - 12752.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. Lemiale, W.-p. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel
Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System
J. Virol., September 15, 2003; 77(18): 10078 - 10087.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. S. Hill
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara
J. Immunol., August 1, 2003; 171(3): 1602 - 1609.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D. T. Evans, L.-M. Chen, J. Gillis, K.-C. Lin, B. Harty, G. P. Mazzara, R. O. Donis, K. G. Mansfield, J. D. Lifson, R. C. Desrosiers, et al.
Mucosal Priming of Simian Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Responses in Rhesus Macaques by the Salmonella Type III Secretion Antigen Delivery System
J. Virol., February 15, 2003; 77(4): 2400 - 2409.
[Abstract] [Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
D. M. Koelle and L. Corey
Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research
Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. S. Morello, M. Ye, and D. H. Spector
Development of a Vaccine against Murine Cytomegalovirus (MCMV), Consisting of Plasmid DNA and Formalin-Inactivated MCMV, That Provides Long-Term, Complete Protection against Viral Replication
J. Virol., April 16, 2002; 76(10): 4822 - 4835.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley
Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge
J. Gen. Virol., January 1, 2002; 83(1): 81 - 91.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.